Should metoprolol be restarted in an elderly patient with persistent atrial fibrillation and sick sinus syndrome who has a newly implanted leadless VVI (ventricular demand) pacemaker and is experiencing near‑syncope and dizziness?

Do Not Restart Metoprolol

In this patient with sick sinus syndrome and a VVI leadless pacemaker experiencing persistent near-syncope and dizziness, metoprolol should NOT be restarted. The VVI pacing mode itself is likely contributing to the symptoms, and adding a beta-blocker would worsen bradycardia and potentially exacerbate hemodynamic compromise.

Why VVI Pacing is Problematic in This Patient

The core issue is that VVI pacing should be avoided in sick sinus syndrome 1. Multiple guidelines explicitly state that physiological pacing (atrial or dual-chamber) is definitively superior to VVI pacing in sick sinus syndrome, with Class I, Level A evidence 1.

The Mechanism of Ongoing Symptoms

Your patient's persistent symptoms are likely due to:

• Pacemaker syndrome: Loss of AV synchrony from VVI pacing causes reduced cardiac output, cannon A waves, and elevated atrial pressures 2, 3
• Loss of atrial contribution: The atrial kick contributes 15-30% of cardiac output, which is lost with ventricular-only pacing
• Potential retrograde VA conduction: This can worsen hemodynamics and cause pulsations, hypotension, and dizziness 2, 4

Recent data confirms this problem: VVI leadless pacemakers in non-AF bradyarrhythmias (including sick sinus syndrome) resulted in significantly increased heart failure readmissions (29% vs 2%) compared to dual-chamber pacing 5.

Why Beta-Blockers Are Contraindicated

Guidelines explicitly warn against beta-blockers in this scenario 1:

• Beta-blockers exacerbate bradycardia in sick sinus syndrome patients and can "create pauses of sufficient duration to result in syncope" 1
• Elimination of offending agents is an important element in preventing syncope recurrence 1
• The FDA label for metoprolol warns of bradycardia, sinus pause, heart block, and cardiac arrest, with particular risk in patients with sinus node dysfunction 6

The Persistent Atrial Fibrillation Consideration

While metoprolol can help with rate control in persistent AF 7, 8, this benefit is negated by:

1. The patient already has a pacemaker providing ventricular rate support
2. The sick sinus syndrome makes them particularly vulnerable to bradycardia from beta-blockade
3. The VVI mode cannot provide AV synchrony regardless of rate control

The Correct Management Approach

The solution is to address the pacing mode, not add medications:

1. Evaluate for pacemaker upgrade: Consider upgrading to a dual-chamber system if technically feasible. This would restore AV synchrony and likely resolve symptoms 1

2. Optimize current device programming:

   • Ensure the lower rate limit is appropriate (not too low)
   • Verify adequate sensing and capture
   • Consider rate-responsive programming if available (VVIR) to improve chronotropic response 1

3. Assess for other causes: Rule out other contributors to symptoms:

   • Volume status
   • Orthostatic hypotension
   • Neurally-mediated syncope (which can coexist with sick sinus syndrome) 1

4. If rate control is absolutely necessary for AF: Only after optimizing the pacing system, and if persistent rapid ventricular rates during AF are documented, consider the lowest possible dose of a rate-controlling agent—but recognize this is suboptimal with VVI pacing

Critical Pitfall to Avoid

Do not assume the pacemaker has "solved" the bradycardia problem and therefore beta-blockers are safe. The guidelines are clear that even with pacing, beta-blockers and other bradycardia-promoting agents should be eliminated when possible in sick sinus syndrome patients with syncope 1. The VVI mode creates a hemodynamic liability that beta-blockers would compound.

The Evidence Hierarchy

The guideline evidence (Class I, Level A) strongly favors avoiding VVI pacing in sick sinus syndrome 1. The 2001 European Heart Journal guidelines explicitly state: "VVI or VVIR pacing should therefore be avoided in sick sinus syndrome" 1. This recommendation has been consistent across multiple guideline iterations from 1991 through 2019 2, 4, 2, 9, 10.

The primary intervention should be reconsidering the pacing strategy, not adding medications that worsen the underlying pathophysiology.